Lung Cancer

Jonathan D'Cunha, MD, PhD, FACS, discusses surgical options for high-risk patients with lung cancer.

Chad Cherington, MD, discusses the use of immunotherapy and targeted therapy in lung cancer.

Luis E. Raez, MD, discusses the role of liquid biopsies in newly diagnosed patients with lung cancer.

Terence T. Sio, MD, MS, discusses the standard-of-care dose of radiation therapy in locally advanced, non–small cell lung cancer.

Michael K. Gould, MD, MS, pulmonologist and director of the Division of Health Services Research and Implementation Science at Kaiser Permanente Southern California, discusses the implications of the NELSON trial in lung cancer.

The FDA has granted a breakthrough therapy designation to JNJ-61186372 for the treatment of patients with EGFR-positive metastatic non–small cell lung cancer who harbor exon 20 insertion mutations, and whose disease has progressed on or after platinum-based chemotherapy.

Amin J. Mirhadi, MD, discusses patient populations of lung cancer who should be treated with radiation therapy.

Michael K. Gould, MD, MS, discusses pivotal lung cancer screening trials and their impact on clinical practice.

Ronald B. Natale, MD, medical director, Clinical Lung Cancer Program and assistant clinical professor of medicine, Cedars-Sinai, discusses the utility of PD-L1 expression and tumor mutational burden (TMB) in lung cancer.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for a Marketing Authorization Application for brigatinib for the first-line treatment of patients with ALK-positive metastatic non–small cell lung cancer

Kavitha Ramchandran, MD, discusses considerations as patients with thoracic malignancies enter palliative care.

Zofia Piotrowska, MD, MHS, discusses the patient populations eligible to receive osimertinib as treatment for lung cancer.

Young Kwang Chae, MD, MPH, MBA, discusses using crizotinib to treat MET-positive patients with non–small cell lung cancer.

Karen L. Reckamp, MD, MS, discusses targeted therapy options for rare mutations in non–small cell lung cancer.

Alain C. Mita, MD, discusses the impact of immunotherapy in the frontline and recurrent settings for patients with small cell lung cancer.

The FDA's Oncologic Drugs Advisory Committee voted 6 to 5 in favor of intravenous ramucirumab injection for use in combination with erlotinib as a frontline treatment for patients with metastatic non–small cell lung cancer whose tumors harbor EGFR exon 19 deletions (Ex19del) or exon 21 (L858R) substitution mutations.